APEIRON Biologics
Apeiron Biologics is developing a potential drug candidate APN01, based on our proprietary ACE2 platform to address the growing global health threat.
Rankings by 
National Ranking
6th
in AustriaRegional Ranking
363rd
in Western EuropeGlobal Ranking
1613th
worldwide